EMSA Services for Protein–DNA & Protein–RNA Interaction Analysis

Q: Can I use nuclear extract instead of purified protein for EMSA?

Yes. Nuclear extracts or whole-cell lysates can be used directly. The identity of the protein responsible for the shift can be confirmed by supershift using an antibody against the candidate factor. Extracts may produce multiple shifted bands; we include protease inhibitors and optimize conditions to maximize complex stability.

Q: How does RNA EMSA differ from DNA EMSA?

RNA EMSA requires: Mg2+ (1-5 mM) for RNA secondary structure stabilization, RNase-free conditions throughout, tRNA as non-specific competitor instead of poly(dI-dC), electrophoresis at 4 degrees C, and probe integrity verification by denaturing gel before each experiment.

Q: How many controls do I need for a publication-quality EMSA figure?

The minimum set: free probe only, protein + wild-type probe (the shift), protein + mutant probe (loss of shift), and specific cold competitor at increasing concentrations. For extracts, add a supershift lane. A well-designed 10-12 lane gel accommodates all controls plus replicates.

Q: What labeling method should I choose?

Biotin-chemiluminescence is most common — high sensitivity without radioactive material. FAM/Cy5 fluorescence enables direct in-gel detection without membrane transfer. 32P remains the gold standard for ultimate sensitivity (sub-pM), preferred when protein is limited or affinity is very weak.

Q: What if there is no shift — does it mean my protein does not bind?

Not necessarily. Absence of a shift can result from complex dissociation during electrophoresis, high buffer ionic strength, inactive or aggregated protein, incorrect binding motif, or missing cofactors. Our troubleshooting protocol systematically addresses each possibility before concluding binding is absent.

Gel Shift Assays for Transcription Factor Validation, RNA-Binding Protein Studies & Sequence-Specificity Confirmation

Creative Proteomics provides electrophoretic mobility shift assay (EMSA) services for direct, visual detection of protein–nucleic acid interactions — the most widely used in vitro method for confirming whether a protein binds a specific DNA or RNA sequence. Our platform supports biotin, FAM-fluorescence, and radioisotope (³²P) labeling, with validated protocols for standard EMSA, competitive EMSA, supershift identification, RNA EMSA, and quantitative KD measurement from purified proteins or nuclear extracts.

EMSA answers a question that ChIP cannot: does your protein bind this sequence directly, and how strongly? Unlike chromatin immunoprecipitation — which reports genomic association but cannot distinguish direct from indirect binding — EMSA isolates the binding event itself, providing direct visual evidence of sequence-specific complex formation. This makes it the definitive method for confirming transcription factor binding sites, validating ChIP-Seq, SELEX, and yeast one-hybrid hits, and detecting RNA–protein interactions that other methods miss.

Core Capabilities:

DNA EMSA — validate transcription factor–promoter interactions, confirm SELEX or ChIP-Seq hits with wild-type vs. mutant probes
RNA EMSA — detect RNA–protein complexes with optimized protocols accounting for RNA secondary structure and degradation sensitivity
Supershift EMSA — confirm the identity of the protein in the complex using a specific antibody that further retards migration
Competitive & Quantitative EMSA — cold-probe competition confirms binding specificity; protein titration generates KD values from dose-response curves

Discuss Your EMSA Project

What Is an Electrophoretic Mobility Shift Assay?

EMSA (also called gel shift assay or gel retardation assay) detects protein–nucleic acid complexes by their slower migration through a native polyacrylamide gel compared to free nucleic acid. A labeled DNA or RNA probe is incubated with the protein of interest; if binding occurs, the complex migrates as a higher-molecular-weight band — the "shift." The presence, intensity, and specificity of this band — tested against wild-type vs. mutant probes and unlabeled competitors — provide direct evidence of sequence-specific binding, relative affinity, and protein identity from a single gel.

Unlike ChIP — which reports genomic association but cannot distinguish direct from indirect binding — EMSA isolates the binding event itself under defined in vitro conditions. With modern fluorescent detection achieving sub-nM sensitivity and well-established titration protocols for KD determination (Hellman & Fried, Nature Protocols, 2007), EMSA combines the interpretability of a gel with the quantitative rigor of a binding assay — remaining the definitive method for confirming protein–nucleic acid interactions.

What Questions Does EMSA Answer?

Does my transcription factor bind this promoter sequence? — A shifted band provides direct, visual confirmation of protein–DNA complex formation.
Is the binding sequence-specific? — Cold specific competitor abolishes the shift; mutant or non-specific competitor does not — confirming motif-dependent binding.
Which protein in my nuclear extract is responsible for the shift? — A supershift antibody further retards the complex, identifying the bound protein.
What is the binding affinity (KD)? — Protein titration at limiting probe concentration generates a binding curve for KD calculation.
Does this inhibitor disrupt the protein–DNA interaction? — Compound titration reveals concentration-dependent loss of the shifted band — directly measuring IC50.
Does my RNA-binding protein interact with this UTR or lncRNA? — RNA EMSA with optimized probe design, Mg²⁺ stabilization, and RNase-free conditions detects complexes other methods miss.

If your research requires direct evidence of protein–nucleic acid binding — rather than inference from genomic association or reporter assays — EMSA provides the definitive answer.

Why EMSA for Protein–Nucleic Acid Interactions?

Quantitative KD from Gel Band Intensities — No Specialized Instrumentation

Protein titration at a fixed, limiting probe concentration — with bound and free band intensities quantified by standard fluorescence or chemiluminescence imaging — generates binding isotherms from which KD is calculated by nonlinear curve fitting. Detection sensitivity reaches below 0.1 nM with modern fluorescent labels, rivaling fluorescence polarization — but using only standard gel electrophoresis equipment present in every molecular biology laboratory.

Sequence Specificity Confirmed Across Adjacent Gel Lanes

Wild-type probe + protein → shift. Mutant probe (2–4 point mutations in the predicted motif) + protein → no shift. This internally controlled comparison — run in adjacent lanes on the same gel — provides irrefutable evidence of motif-dependent binding. Adding unlabeled specific competitor at increasing concentrations (10×, 50×, 100×) progressively extinguishes the shift while a non-specific competitor leaves it intact — confirming sequence specificity in a single figure.

No Purification Required — Works Directly with Nuclear Extracts

EMSA accepts purified protein, nuclear extracts, whole-cell lysates, or in vitro translation products — as little as 0.5–5 µg per lane depending on probe affinity and detection method. When working with complex mixtures, a supershift antibody against the candidate DNA-binding protein produces a further-retarded ternary complex, identifying the specific protein responsible for the shift without prior purification.

One Workflow — DNA and RNA Probes

The same labeling, binding, electrophoresis, and detection workflow applies to both DNA and RNA. RNA EMSA adds Mg²⁺ (1–5 mM) for secondary structure stabilization, RNase-free conditions, and probe design accounting for folding — but produces the identical, directly interpretable readout: a shifted band at the RNA–protein complex position. This is particularly valuable for lncRNA and mRNA UTR studies where alternative methods (ChIP, footprinting) are inapplicable.

Technical Services

Capabilities Method Comparison Workflow Controls & QC Sample Requirements Deliverables FAQ Get a Proposal

EMSA & Gel Shift Assay Services

Five assay formats cover the full range of protein–nucleic acid binding questions — from simple yes/no confirmation through quantitative KD measurement and inhibitor screening.

Standard EMSA — Binding Validation

Confirm whether a purified protein or nuclear extract binds a specific DNA or RNA probe
Wild-type vs. mutant probe comparison verifies motif-dependence of binding
Detection: biotin-chemiluminescence, FAM fluorescence, or ³²P radioisotope
Typical output: gel image with free probe lane, protein + probe lane, and mutant probe control

Competitive EMSA — Specificity Confirmation

Unlabeled specific competitor probe added in increasing excess — shift intensity decreases dose-dependently
Non-specific competitor (unrelated sequence) leaves the shift unaffected — confirming sequence-specificity
Quantifies relative affinity: stronger binders require higher competitor excess to compete away the shift
Essential control for distinguishing specific binding from non-specific stickiness

Supershift EMSA — Protein Identity Confirmation

Antibody against the candidate DNA/RNA-binding protein is added to the binding reaction
Antibody–protein–probe ternary complex migrates as a further-retarded "supershifted" band
Confirms the specific protein responsible for the shift — critical when working with nuclear extracts or lysates
Requires IP-grade or ChIP-grade antibody validated for native protein recognition

RNA EMSA — RNA–Protein Interaction Detection

Optimized for RNA probes — Mg²⁺ stabilization of secondary structure, RNase-free conditions throughout
Probe design accounts for RNA folding: motif probes for clear yes/no binding; context probes for biological relevance
Suitable for mRNA UTRs, lncRNAs, viral RNA elements, and ribonucleoprotein complexes
RNA-specific controls: free probe, protein-only, and competitor RNAs to confirm specificity

Quantitative EMSA — Affinity Measurement & Drug Screening

Protein titration at limiting, fixed probe concentration generates a binding isotherm — band intensity vs. [protein]
Nonlinear curve fitting yields apparent KD — directly comparable across proteins, mutants, or conditions
Compound/inhibitor titration measures IC50 for small molecules that disrupt protein–DNA interactions
Enables rank-ordering of transcription factor inhibitors or mutant binding defects in a single experimental format

EMSA vs. Other Protein–Nucleic Acid Interaction Methods

Different methods answer different questions. Choose based on whether you need direct binding evidence (EMSA), genomic occupancy (ChIP), kinetics (SPR), or binding-site resolution (DNase I footprinting), or affinity-based identification of DNA-binding proteins by DNA pull-down with MS readout.

Feature	EMSA	ChIP (Chromatin IP)	SPR	DNase I Footprinting
Detects	Direct protein–DNA complex formation in vitro	Protein association with genomic loci in vivo	Real-time binding kinetics (ka/kd/KD)	Protein–DNA binding site at single-nucleotide resolution
Distinguishes Direct vs. Indirect Binding	Direct only — EMSA isolates the binding event	No — crosslinked complexes may be indirect	Direct only	Direct only
Sequence Specificity	Confirmed in one experiment (wt vs. mutant + competition)	Inferred from peak location	No direct sequence information	Single-nucleotide footprint on the DNA
Quantitative KD	Yes — protein titration under limiting probe	No — occupancy, not affinity	Yes — gold standard for kinetics	No
Sample State	In vitro — purified protein or extracts	In vivo — crosslinked cells/tissue	In vitro — purified, surface-immobilized	In vitro — purified protein + DNA
Protein Identity via Supershift	Yes — antibody supershift confirms protein in complex	Yes — antibody-based enrichment	No — requires pure protein	No — requires pure protein
RNA-Compatible	Yes — RNA EMSA with optimized conditions	No — DNA only	Yes — RNA immobilization possible	No — DNA only
Sample Required	50–100 ng probe; 0.5–5 µg protein per lane	10⁶–10⁷ cells per IP	5–50 µg protein for immobilization	100–500 ng DNA; purified protein
Best For	Direct binding confirmation, sequence specificity, TF binding site validation, RNA–protein complexes, drug screening	Genome-wide TF occupancy, histone modification mapping, in vivo binding	Kinetic rate constants, affinity ranking, real-time binding	Precise binding-site mapping at nucleotide resolution

EMSA Workflow: From Probe to Publication-Ready Gel Image

Project consultation & probe design

Review of protein source (purified, extract, or in vitro translated), target sequence, and research question
Probe design: wild-type + mutant sequences; fluorophore or biotin labeling strategy; RNA probes include secondary structure assessment
Selection of assay mode: standard, competitive, supershift, or quantitative

Probe synthesis & quality control

DNA probes: HPLC-purified oligonucleotides, 5'- or 3'-labeled with biotin, FAM, Cy5, or ³²P (for radioisotope option)
RNA probes: in vitro transcribed or synthetic; integrity verified by denaturing gel; quantified by spectrophotometry
Annealing of complementary strands for double-stranded probes; structural validation by native PAGE

Binding reaction optimization

Buffer: Tris or HEPES with monovalent salt (50–150 mM KCl/NaCl), ± Mg²⁺ (1–5 mM for RNA), DTT (0.5–1 mM), glycerol (5–10%), non-specific competitor (poly(dI-dC) or tRNA)
Incubation: 20–30 min at 4°C, room temperature, or 37°C — optimized per probe–protein pair
Competitor or antibody pre-incubation for competitive and supershift modes

Native PAGE & electrophoresis

4–6% native polyacrylamide gel (or 4–20% gradient for broad molecular weight range)
Pre-run at 4°C; electrophoresis at constant low voltage (80–120 V) to prevent complex dissociation and gel heating
Free probe lane included in every gel as migration reference

Detection & imaging

Biotin-labeled probes: membrane transfer + streptavidin-HRP + chemiluminescence detection
Fluorescent probes (FAM, Cy5): direct gel imaging on fluorescence scanner
³²P-labeled probes: autoradiography or phosphorimaging for highest sensitivity (sub-pM detection limit)
Band intensities quantified by densitometry for KD determination

Data analysis & reporting

Shift confirmation, specificity assessment (competition + mutant probe lanes), and supershift interpretation
For quantitative EMSA: binding curve fitting (Hill or one-site specific binding model), KD and 95% confidence interval
Full experimental report with gel images, densitometry data, curve fits, methods, and interpretation

Controls & Quality Standards for EMSA

The difference between a publication-quality EMSA and an inconclusive one is in the controls. Every EMSA experiment includes a minimum control set to ensure results are interpretable and defensible.

Control Lane	What It Shows	Interpretation
Free probe only	Unbound labeled probe migration position	Establishes baseline migration; free probe should be a single, sharp band — smearing indicates probe degradation
Protein + wild-type probe	Shifted complex band	Presence of shifted band = binding; absence = no detectable interaction under these conditions
Protein + mutant probe	Binding to a probe with the predicted binding motif disrupted	Loss or reduction of shift confirms motif-dependent, sequence-specific binding
Specific cold competitor	Unlabeled wild-type probe added at 10–100× excess	Progressive loss of shifted band confirms the shift is due to specific probe binding, not non-specific stickiness
Non-specific cold competitor	Unlabeled unrelated-sequence probe at same excess	Shift should persist — if it also disappears, binding is non-specific or the competitor has sequence similarity
Supershift antibody	Antibody against candidate binding protein	Further-retarded band confirms the identity of the protein in the complex; antibody alone (no protein) should not produce a shift
Protein-only (no probe)	Control for protein detection artifacts	Should show no signal in the probe detection channel — confirms the signal is probe-specific

For quantitative EMSA experiments, an additional control lane at saturating protein concentration is included to define the maximum shift intensity (Bmax) for curve fitting. Every gel image is delivered with lane annotations identifying each control and its purpose — ensuring reviewers can follow the full logic chain in a single figure.

Sample Requirements for EMSA

Sample Type	Requirements
Purified DNA-Binding Protein	Minimum 5–10 µg at ≥0.1 mg/mL; provide in storage buffer (Tris or HEPES with salt, glycerol, and DTT); avoid denaturing agents (SDS, urea) that must be removed before the binding reaction
Nuclear Extract / Cell Lysate	Minimum 50–100 µg total protein at ≥1 mg/mL; provide extraction method details; extracts must be free of protease activity; include empty-vector or mock-transfected control extract if available
Target DNA/RNA Sequence	Provide the wild-type binding sequence (20–60 bp for DNA; 20–80 nt for RNA) plus a negative-control mutant sequence where the predicted binding motif is disrupted by 2–4 point mutations
Antibody for Supershift	IP-grade or ChIP-grade antibody, 10–50 µg; must recognize the native (non-denatured) protein; provide validation data if available — not all antibodies work in EMSA supershift
Small Molecule / Inhibitor (for drug screening)	1–5 mg of compound at known purity; soluble in DMSO (≤2% final) or aqueous buffer; provide vehicle-only control; concentration range for IC50 determination discussed during consultation
Shipping	Purified proteins and extracts: ship on dry ice; antibodies: ship on cold packs; oligonucleotides/RNA: ship at ambient or on dry ice (RNA); avoid repeated freeze-thaw cycles

Deliverables for EMSA Studies

Annotated Gel Images, Quantitative Analysis, and Full Experimental Documentation

Every EMSA project includes complete gel images with lane-by-lane annotations, densitometry data, and a detailed methods section suitable for publication.

Annotated EMSA Gel Images

Full gel images with each lane labeled by condition (free probe, wt probe, mutant probe, competitor concentrations, supershift antibody). Band annotations identify the free probe, shifted complex, and supershifted complex for unambiguous interpretation.

Densitometry & Binding Curves

Band intensity quantification with background subtraction. For quantitative EMSA: protein titration binding curves with nonlinear fit, KD values with 95% confidence intervals, and Hill coefficients where applicable.

Competition & Specificity Data

Dose-dependent competition gel showing progressive loss of the shifted band with increasing unlabeled specific competitor (10×, 50×, 100×). Non-specific competitor lane confirms sequence-specificity. Mutant probe lane (no shift) validates motif-dependence.

Frequently Asked Questions About EMSA

What is the difference between EMSA and ChIP for studying transcription factor binding?

EMSA detects direct protein–DNA complex formation in a controlled in vitro system — it confirms whether the protein physically binds a specific DNA sequence. ChIP detects protein association with genomic loci in cells — including indirect associations through protein complexes or chromatin. For example, a ChIP peak at a promoter could reflect the TF binding directly, or it could reflect the TF being recruited by another DNA-binding protein. EMSA resolves this ambiguity: if the purified TF shifts the promoter probe, binding is direct. Many investigators use ChIP to identify candidate binding regions genome-wide, then EMSA to confirm direct, sequence-specific binding at individual sites of interest.

Can I use nuclear extract instead of purified protein for EMSA?

Yes — this is one of EMSA's key advantages. Nuclear extracts or whole-cell lysates can be used directly, with the shifted band representing the collective binding activity in the extract. The identity of the specific protein responsible for the shift can then be confirmed by supershift using an antibody against the candidate factor. However, extracts may contain multiple proteins that bind the same probe, producing multiple shifted bands or a diffuse shift. Extracts also carry higher nuclease and protease activity, which can degrade the probe or protein during incubation. We include protease/phosphatase inhibitors and optimize incubation conditions to maximize complex stability when working with extracts.

What labeling method should I choose — biotin, fluorescent, or radioisotope?

Biotin-chemiluminescence is the most common choice — it provides high sensitivity (comparable to ³²P in many cases), avoids radioactive material handling, and uses standard Western blot imaging equipment. FAM or Cy5 fluorescence enables direct in-gel detection without membrane transfer — faster workflow, but typically requires a fluorescence imager. ³²P radioisotope labeling remains the gold standard for ultimate sensitivity (sub-pM detection) and is preferred when protein is extremely limited or binding affinity is very weak. The choice depends on your sensitivity requirements, available equipment, and institutional safety constraints. Our team can advise during consultation.

How does RNA EMSA differ from DNA EMSA?

RNA EMSA requires several protocol modifications: (1) Mg²⁺ (1–5 mM) in the binding buffer and gel to stabilize RNA secondary structure, (2) RNase-free conditions throughout — all buffers, gel apparatus, and pipette tips must be RNase-free, (3) RNA probes are more sensitive to degradation — probe integrity is verified by denaturing gel before each experiment, (4) non-specific competitor is typically tRNA rather than poly(dI-dC), and (5) electrophoresis is typically run at 4°C to further suppress RNase activity. The fundamental readout — a shifted band confirming complex formation — is identical to DNA EMSA.

How many controls do I need for a publication-quality EMSA figure?

The minimum set expected by reviewers includes: (1) free probe only lane, (2) protein + wild-type probe (the shift), (3) protein + mutant probe (loss of shift confirms motif-dependence), and (4) specific cold competitor at increasing concentrations (progressive loss of shift confirms sequence-specificity). For extract-based EMSA, add a supershift lane with antibody against the candidate protein. For quantitative EMSA, include a saturating protein concentration lane to define Bmax. A well-designed 10–12 lane gel can accommodate all these controls plus replicates in a single figure that tells the complete binding story.

What if there is no shift — does it mean my protein does not bind?

Not necessarily. Absence of a shift can result from several factors beyond true lack of binding: (1) the complex dissociates during electrophoresis — try lower voltage or 4°C running conditions, (2) buffer ionic strength is too high — salt concentrations above 150 mM can weaken or abolish binding, (3) the protein is inactive or aggregated — verify activity by an independent method, (4) the probe lacks the correct binding motif — verify the sequence against known binding site data, (5) cofactors or post-translational modifications required for binding are absent. Our troubleshooting protocol systematically addresses each possibility before concluding that binding is absent.

Key Literature on EMSA Methodology & Applications

Suresh, S.K. (2024). Beginner's guide to investigating protein:DNA interactions using electrophoretic mobility shift assays (EMSAs). The Biochemist. 46(5):8-14. DOI: 10.1042/bio_2023_125
— Most recent practical guide covering essential controls, optimization parameters, and interpretation rules for EMSA experiments.

Hellman, L.M. & Fried, M.G. (2007). Electrophoretic mobility shift assay (EMSA) for detecting protein-nucleic acid interactions. Nature Protocols. 2(8):1849-1861. DOI: 10.1038/nprot.2007.249
— Definitive protocol for quantitative EMSA with detailed instructions for generating binding curves and calculating KD.

Holden, N.S. & Tacon, C.E. (2011). Principles and problems of the electrophoretic mobility shift assay. Journal of Pharmacological and Toxicological Methods. 63(1):7-14. DOI: 10.1016/j.vascn.2010.03.002
— Reviews common EMSA pitfalls with solutions for non-specific binding, weak shifts, supershift failures, and quantification issues.

Fried, M.G. & Crothers, D.M. (1981). Equilibria and kinetics of lac repressor-operator interactions by polyacrylamide gel electrophoresis. Nucleic Acids Research. 9(23):6505-6525. DOI: 10.1093/nar/9.23.6505
— Seminal paper establishing EMSA as a quantitative method for measuring protein-DNA binding equilibria — the foundation of quantitative gel shift analysis.

Ryder, S.P. et al. (2008). Purification of sequence-specific DNA-binding proteins by affinity chromatography. Current Protocols in Protein Science. 53:9.6.1-9.6.30. DOI: 10.1002/0471140864.ps0906s53
— Includes comprehensive EMSA protocols for monitoring purification of DNA-binding proteins and validating binding activity throughout the purification workflow.